LOS ANGELES - Enrollment has begun to test additional investigational drugs to fight COVID-19 symptoms, the National Institutes of Health (NIH) announced Friday.Testing started through the "Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)" program, which prioritizes and speeds up development of promising COVID-19 treatments and vaccines.The studies will test several new interventions for safety and efficacy:The first volunteer enrolled in the SNG001 sub-study on Feb.
10. The other studies are expected to begin enrolling participants soon. The trial will allow for comparison of multiple interventions with a shared group of placebo recipients."To ensure that the trial is being conducted in a safe and effective manner, an.